MedImmune Inc. said Tuesday that it has sold 2.5 millionshares of common stock priced at $43.50 per share in a publicoffering. The company, which sold 500,000 newly issuedshares, grossed $21.8 million. The remaining 2 million shareswere sold by shareholders.
After the offering, the Gaithersburg, Md., developer oftherapeutics and vaccines for infectious diseases and cancershas 13.2 million shares outstanding.
MedImmune shares (NASDAQ:MEDI) rose 25 cents to $43.75 onTuesday.
Underwriters Morgan Stanley & Co. Inc. and Smith Barney,Harris Upham & Co. Inc. have a 375,000-share overallotmentoption, of which 75,000 shares would be issued by thecompany and 300,000
(c) 1997 American Health Consultants. All rights reserved.